Pharma BD Deal Intelligence
Vertex acquired Alpine Immune Sciences for $4.9B.
Vertex Pharma bolsters its immunology profile with $4.9 billion Alpine Immune Sciences acquisition, expanding beyond cystic fibrosis into chronic kidney…
FDA accepted Vertex's Biologics License Application for accelerated approval of povetacicept in IgA nephropathy, with a PDUFA target action date of November…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Vertex Pharmaceuticals acquired Alpine Immune Sciences for $65 per share, ~$4.9 billion in cash (a ~67% premium and the largest acquisition in Vertex's history at the time), with the deal closing May 20, 2024. The strategic rationale was povetacicept, a dual BAFF/APRIL inhibitor fusion protein, as the centerpiece of Vertex's expansion beyond cystic fibrosis into nephrology and autoimmune disease. The thesis has since been validated: on March 9, 2026 the Phase 3 RAINIER trial in IgA nephropathy met its primary and all secondary endpoints at the Week 36 interim analysis (~52% reduction in urine protein-to-creatinine ratio from baseline; 49.8% vs placebo, P<0.0001), and on June 1, 2026 the FDA accepted Vertex's BLA for accelerated approval with a PDUFA target action date of November 30, 2026 under Breakthrough Therapy Designation. If approved, povetacicept would become the first commercialized product in Vertex's nephrology franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences (this deal) | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
| Vertex Pharmaceuticals Incorporated / ViaCyte Inc. | 2022 | $320M | 60 |
← Browse all deals · How we score deals
More: 2024 deals · Vertex Pharmaceuticals Incorporated deals · Immunology deals